Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Total Liabilities (2022 - 2025)

Historic Total Liabilities for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $133.7 million.

  • BioXcel Therapeutics' Total Liabilities fell 60.51% to $133.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.7 million, marking a year-over-year decrease of 60.51%. This contributed to the annual value of $131.4 million for FY2024, which is 94.39% up from last year.
  • According to the latest figures from Q3 2025, BioXcel Therapeutics' Total Liabilities is $133.7 million, which was down 60.51% from $133.5 million recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year Total Liabilities high stood at $154.7 million for Q1 2024, and its period low was $17.0 million during Q1 2022.
  • Moreover, its 4-year median value for Total Liabilities was $131.4 million (2024), whereas its average is $122.5 million.
  • As far as peak fluctuations go, BioXcel Therapeutics' Total Liabilities soared by 64653.74% in 2023, and later tumbled by 1677.46% in 2025.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Total Liabilities stood at $129.1 million in 2022, then rose by 0.88% to $130.2 million in 2023, then rose by 0.94% to $131.4 million in 2024, then rose by 1.73% to $133.7 million in 2025.
  • Its last three reported values are $133.7 million in Q3 2025, $133.5 million for Q2 2025, and $128.7 million during Q1 2025.